Mogamulizumab (KW-0761) 是一种去岩藻糖基化的重组抗 CCR4单克隆抗体 (MAb)。Mogamulizumab 可以通过抗体依赖性细胞毒性 (ADCC) 消除肿瘤细胞。Mogamulizumab 可用于癌症、成人T细胞白血病/淋巴瘤 (ATLL)、皮肤T细胞淋巴瘤 (CTCL) 的研究。
| 生物活性 | Mogamulizumab (KW-0761) is a defucosylated humanized recombinantanti-CCR4monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3) in the presence of PBMCs[2].
Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation in PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP)[3].
Mogamulizumab (1 μg/mL, 5 days) eliminates the CD4+CCR4+T cells in cultured PBMCs from patients with HAM/TSP[3].
|
体内研究
(In Vivo) | Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model[2].
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+T cells, with no adverse effect in dogs[4].
| Animal Model: | Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)[2] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks. | | Result: | Suppressed Tumor growth with vacuolar degeneration. |
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
